<DOC>
	<DOCNO>NCT03049189</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Peptide Receptor Radionuclide Therapy ( PRRT ) 177Lu-Edotreotide compare targeted molecular therapy Everolimus patient inoperable , progressive , somatostatin receptor-positive ( SSTR+ ) , neuroendocrine tumour gastroenteric pancreatic origin ( GEP-NET ) .</brief_summary>
	<brief_title>Efficacy Safety 177Lu-edotreotide PRRT GEP-NET Patients</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Edotreotide</mesh_term>
	<criteria>Histologically clinically confirm diagnosis welldifferentiated neuroendocrine tumour nonfunctional gastroenteric origin ( GENET ) functional nonfunctional pancreatic origin ( PNET ) Measurable disease per RECIST 1.1 Somatostatin receptor positive ( SSTR+ ) disease Radiological disease progression , define progressive disease per RECIST 1.1. criterion Known hypersensitivity edotreotide everolimus Known hypersensitivity DOTA , lutetium177 , excipient edotreotide everolimus Prior exposure peptide receptor radionuclide therapy ( PRRT ) Prior therapy mTor inhibitor Prior EFR ( extended field radiation ) GEPNET lesion radioembolisation therapy Therapy investigational compound and/or medical device within 30 day prior randomisation Indication surgical lesion removal curative potential Planned alternative therapy ( period study participation ) Serious nonmalignant disease Renal , hepatic , cardiovascular , haematological organ dysfunction , potentially interfere safety study treatment Pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>non-functional functional P-NET</keyword>
	<keyword>non-functional GE-NET</keyword>
</DOC>